Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:30pm, Thursday, 31'st Dec 2020
CAMBRIDGE, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2020 tha
Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst
02:00pm, Friday, 18'th Dec 2020
Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ:
Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
09:07am, Thursday, 17'th Dec 2020
MENLO PARK, Calif.--(BUSINESS WIRE)---- $SRPT #PrecisionOncology--Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development
Sarepta Therapeutics Announces Executive Management Changes
08:30am, Monday, 14'th Dec 2020
-- Ian Estepan named chief financial officer -- Dallan Murray named chief commercial officer -- Louise Rodino-Klapac, Ph.D., named chief scientific officer -- Ty Howton, general counsel, to retire fro
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference (Transcript)
-- Results from the multiple - ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than eteplirs
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020 a
Sarepta Therapeutics, Inc. (SRPT) Presents at Evercore ISI HealthCONx Conference - (Transcript)
06:01pm, Wednesday, 02'nd Dec 2020
Sarepta Therapeutics, Inc. (SRPT) Presents at Evercore ISI HealthCONx Conference - (Transcript)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:05pm, Monday, 30'th Nov 2020
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2020 tha
Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
08:30am, Wednesday, 25'th Nov 2020
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pa
Sarepta Therapeutics Named One of The Boston Globe's Top Places to Work 2020
08:30am, Friday, 20'th Nov 2020
-- Sarepta is h onored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- -- Rankings based on confidential survey information
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)
12:09am, Tuesday, 10'th Nov 2020
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2020 Results - Earnings Call Transcript
10:42pm, Thursday, 05'th Nov 2020
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2020 Results - Earnings Call Transcript
Sarepta Therapeutics Posts Mixed Third Quarter As Sales Miss
04:21pm, Thursday, 05'th Nov 2020
Sarepta Therapeutics reported third-quarter losses of $1.42 per share on $121.4 million in sales late Thursday. But SRPT stock was flat in extended trades.
-- Dosing with SRP-9001 commercial-process material to proceed following discussions with U.S. FDA -- -- Clinical d osing is expected to begin b efore the end of 2020 --
